Paramagnetic chelates, as for example, Gadolinium diethylenetriaminepentaacetic acid (DTPA), manganese, ethylenediaminetetraacetic acid (EDTA), and others used as magnetic resonance imaging contrast agents are more toxic acutely when injected in high concentration or at rapid rates. The use of effective amounts of calcium in the form of, calcium chloride, calcium gluconate, or balanced salt solutions substantially reduces this toxicity without the need to add additional ligand.
|
1. In a method for enhancing safety in the in vivo use of methal-ligand chelate complexes as magnetic resonance imaging agents comprising administering to a mammal a diagnostically effective amount of a metal-ligand complex, the improvement comprising: adding calcium ions to a charge-balanced metal-ligand complex formed from the anion of a complexing acid and a central ion of an element with an atomic number of 21 to 29, 42, 44, or 57-70, said calcium ions being added in substantially less than stoichiometric amounts to the metal-ligand complex, said calcium ions being provided from a member of the group consisting of inorganic calcium salts, organic calcium salts and mixtures thereof without excess ligand being added.
13. In a method for enhancing safety in the in vivo use of methal-ligand chelate complexes as magnetic resonance imaging agents comprising administering to a mammal a diagnostically effective amount of a metal-ligand complex, the improvement comprising: adding calcium ions to a charge-balanced metal-ligand complex formed from the anion of a complexing acid and a central ion of an element with an atomic number of 21 to 29, 42, 44, or 57-70, said calcium ions being added in substantially less than stoichiometric amounts to the metal-ligand complex, said calcium ions being provided from a member of the group consisting of inorganic calcium salts, organic calcium salts and mixtures thereof and being added in addition to any calcium present as the salt of an excess of said ligand.
4. The method of
5. The method of
6. The method of
7. The method of
8. The method of
9. The method of
10. The method of
11. The method of
12. The method of
|
|||||||||||||||||||||||||
This is a continuation of application Ser. No. 01/068,588 filed June 30, 1987 now abandoned.
This invention relates to magnetic resonance imaging complexes and more particularly to methods for reducing the toxicity thereof.
It has been found that physiologically well-tolerated complex salts formed from the anion of a complexing acid (ligand) and one or more central ions of an element with a atomic number of 21 to 29, 42, 44 or 57 to 83 (paramagnetic metal) and, optionally, also formed from one or more physiologically biocompatible cations of an inorganic and/or organic base or amino acid, are suitable for producing diagnostic media for use in magnetic resonance imaging or X-ray diagnosis. We have referred to these materials as paramagnetic metal chelates. U.S. Pat. No. 4,647,447 describes the use and the manufacture of paramagnetic metal chelates in detail.
However, it has been found that these paramagnetic chelates employed in magnetic resonance imaging acutely reflect more toxicity when injected in high concentration or at rapid rates. Generally, this toxicity has been manifested as strong convulsions.
Believing this toxicity to stem from the absorption of free paramagnetic metals in the blood, it has been the previous practice to reduce such toxicity by formulating with an additive of excess ligand such as EDTA as its sodium and/or calcium salts. These additives were employed as scavengers for the paramagnetic metal in the manner disclosed by Bernard Osler et al. in Toxicology and Applied Pharmacology, Volume 5, Pages 142-162 published in 1963 under title of "Safety Evaluation Studies of Calcium EDTA".
However, a method for reducing such toxicity without the need for employing excess ligand and without having to correlate the amount of excess ligand to the projected amount of free metal in the blood would be a substantial advancement in the art.
It is an object of this invention to provide enhanced safety in magnetic resonance imaging (MRI) by reducing the toxicity of paramagnetic chelate formulations.
It is a further object of this invention to provide enhanced safety in X-ray contrast imaging by reducing the toxicity of heavy metal chelates.
Upon further study of the specification and appended claims, further objects and advantages of this invention will become apparent to those skilled in the art.
It has been found that adding calcium ions in substantially less than stoichiometric proportions to the metal-ligand chelates used in MRI or X-ray contrast formulation will substantially reduce the acute intravenous toxicity thereof.
In accordance with the present invention, calcium in the form of calcium gluconate, calcium chloride or other suitable organic or inorganic salts and including suitable soluble calcium forms of the chelant/ligand used to complex paramagnetic and/or heavy metals are added to the product formulation to be used for MRI or X-ray contrast imaging.
The calcium ions are added at levels ranging from 1-25% of stoichiometry based on the chelant/ligand concentration, but preferably from 3% to about 15% of stoichiometry.
The amount of calcium added is determined individually for each formulation and will depend on the calcium chelation potential of the formulation. The calcium can be added in a single form, e.g. calcium chloride, or as mixtures, e.g. calcium chloride and calcium gluconate.
The paramagnetic and/or heavy metal chelates to which calcium is to be added are complex salts formed from the anion of a complexing acid and a central ion of an element with an atomic number of 21 to 29, 42, 44 or 57 through 83 and, optionally, also formed from one or more physiologically bio-compatible salts of inorganic and/or organic bases or amino acids. They are suitable for producing diagnostic media which are useful in magnetic resonance imaging and/or X-ray diagnosis. If the medium is intended to be used in magnetic resonance imaging, the central ion must be paramagnetic. It preferably is the divalent or trivalent ion of elements with an atomic number of 21 to 29, 42, 44 and 57 through 70. Suitable ions for example, chromium 3, manganese 2, iron 3, iron 2, cobalt 2, copper 2, praseodymium 3, neodymium 3, samarium 3, ytterbium 3 and because of their very strong magnetic moments gadolinium 3, terbium 3, dysprosium 3, holmium 3, and erbium 3 are preferred.
If the medium is intended for use in X-ray diagnosis, the central ion should be derived from an element with a higher atomic number to achieve a sufficient absorption of X-rays. It has been found that diagnostic media containing a physiologically well-tolerated complex salt with central ions of elements with atomic number of 57 to 83 are suitable for this purpose. These include, for example, lanthanium 3, the above-mentioned ions of the lanthanide group, gold 3, lead 2 and bismuth 3.
The action of citric acid, ethylenediaminetetracetic acid (EDTA) and similar ligands to complex with ionic calcium when injected in-vivo into the bloodstream and inducing tetanic convulsions has long been appreciated. Calcium, administrated as a chloride salt or as calcium gluconate is known to be effective in counteracting these convulsions. However, such teachings have previously found little application in reducing the toxicity of magnetic resonance imaging agents or X-ray contrast agents. Among the prior art reasons for not resorting to ionic calcium in such applications may have been that ionic calcium if added at stoichiometric amounts would have been detrimental because these hypertonic solutions would then have provided excessive amounts of calcium upon injection into the bloodstream. Additionally, calcium complexation by iodinated X-ray contrast media was not significant compared to the newer paramagnetic complexes.
Complex paramagnetic chelates and heavy metals complexed to chelant ligands as previously stated have limited clinical utility at increasing dosages because of the toxicity created therefrom. Toxicity which is usually greater when the agents are injected rapidly and/or at more concentrated levels is generally attributed to the in-vivo release of the heavy metal. Therefore, the addition of excess ligand to the formulation to bind any "free" metal in the injectable is felt to be of value. However, the effective scavaging amount of excess ligand at, for example, 15% excess sodium salt fails to enhance the safety of the Na2 GdDTPA. Addition of 15% excess ligand as the CaNa3 DTPA to NA2 GdDTPA increased the intravenous LD50 about 20%. Although this level of excess ligand would provide about 4 mg/ml of calcium, the following examples show that further enhancement of safety can be expected by adjusting the level of calcium simply by addition of calcium chloride, i.e. without need for excess ligand.
The toxicity of the preferred embodiments of the present invention are measured by lethal dose (LD) values which are approximations of the doses at which the specimen animals die. Exemplary lethal dose values for the present invention are seen in the examples set forth below:
The intravenous LD50 for calcium chloride (CaCl2) in the mouse is reported to be 42 mg/kg (RTECS). This calculates to about 15 mg/kg of calcium or about 0.3 mg of calcium for a 20 gram mouse. When calcium chloride was added to 0.68M disodium gadolinium diethyenetriaminepentaacetic acid (Na2 GdDTPA) at 130 mg/kg (6.5 mg/ml) or 260 mg/kg (13.0 mg/ml) the lethal effects of the Na2 GdDTPA were greatly diminished even though these levels of added calcium would provide 47 and 94 mg/kg, i.e. 0.94 and 1.88 mg respectively to a 20 gram mouse. These values are 3.1 and 6.2 times higher than the i.v. LD50 of calcium administered as CaCl2. Whereas 4 of 4 mice given 13.6 mMol/kg of Na2 GdDTPA alone died, only 1 of 4 mice died at those doses of Na2 GdDTPA with 2.34 mg/ml of added calcium and 2 of 4 died at the 4.68 mg/ml level of added calcium. Clearly then the 0.68 m Na2 GdDTPA solution must complex a substantial amount of the added calcium in a way to block the calcium's in-vivo toxicity.
Conversely, the calcium added to the Na2 GdDTPA formulation blocks the in vivo calcium complexation by Na2 GdDTPA and thereby reduces its toxicity, i.e. prevents tetanic convulsions and death. Clearly this protective effect of added calcium must be balanced to the calcium complexing potential of the paramagnetic contrast agent.
Addition of calcium chloride at 430 (21.5 mg/ml and 860 mg/kg (43 mg/ml), i.e. at 155 and 310 mg of calcium /kg, results in doses of 3.1 and 6.2 mg of calcium per 20 gram mouse. These doses of calcium added to 0.68 m Na2 GdDTPA were not protective and did not enhance the safety of the Na2 GdDTPA formulation. All mice injected with 0.65 m NAGdDTPA at those two dose levels of calcium died. It may be inferred that these levels of added calcium were excessive and exceeded the calcium binding optimum of the solution and that death from calcium toxicity ensued.
In these examples 1 and 2 (see Table 1) it is shown that calcium added to 0.68 m Na2 GdDTPA as calcium chloride at concentrations of 6.5, 13.0, 21.5 and 43 mg/ml of solution and which would result in concentrations of calcium of 2.34 mg, 4.68 mg, 7.74 mg and 15.48 mg per milliliter respectively, provided different levels of protection against the toxicity of Na2 GdDTPA. On a stoichiometric basis the four added calcium levels approximate 9%, 17%, 29% and 57% respectively of the 0.68 m concentration of Na2 GdDTPA. Based on this data, concentrations of added calcium of 30-60% stoichiometric to that of the subject formulation are excessive and do not enhance the safety. However, concentrations of added calcium of 9-17% stoichiometry to the subject formulation were protective based on acute toxicity determinations.
Clearly the optimum amount of calcium to be added will vary based on the ligand chosen and its concentration in the forumulation.
| TABLE 1 |
| __________________________________________________________________________ |
| STUDIES ON INTRAVENOUS TOXICITY OF Na2 GdDTPA ALONE |
| AND ADDED CaCL2 |
| Mice Calcium, % |
| Dose of Added No. No. Approximate |
| Stoichiometry to |
| Na2 GdDTPA |
| Calcium mg/ml |
| Deaths/Injected |
| LD Values |
| Na2 GdDTPA |
| __________________________________________________________________________ |
| 13.6 mMol/kg |
| 0 4/4 100% 0 |
| 13.6 mMol/kg |
| 2.34 1/4 25% 9% |
| 13.6 mMol/kg |
| 4.68 2/4 50% 17% |
| 13.6 mMol/kg |
| 7.74 4/4 100% 29% |
| 13.6 mMol/kg |
| 15.48 2/2 100% 57% |
| __________________________________________________________________________ |
| Patent | Priority | Assignee | Title |
| 5204085, | Jan 08 1985 | Mallinckrodt Medical, Inc. | Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents |
| 5219553, | Aug 04 1986 | AMERICAN HEALTH SALUTAR INC | Composition of a n-carboxymethylated tetraazacyclododecane chelating agent, a paramagnetic metal and excess calcium ions for MRI |
| 5516503, | Nov 16 1989 | Guerbet S.A. | Diagnostic composition comprising a binuclear complex, its method of preparation and its use in magnetic resonance imaging |
| 5876695, | Nov 28 1986 | Bayer Schering Pharma Aktiengesellschaft | Metal complex-containing pharmaceutical agents |
| 5980863, | Nov 02 1998 | Eagle Vision Pharmaceutical Corporation | Manganese compositions and methods for MRI |
| 6559330, | Sep 09 1999 | Bayer Schering Pharma Aktiengesellschaft | CALCIUM COMPLEX OF [[(4R)-4-[BIS{CARBOXY-.KAPPA.O)METHYL]AMINO-.KAPPA.N]-6,9-BIS[(CARBOXY.KAPPA.O)METHYL]-1-[(4,4-DIPHENYLCYCLOHEXYL)OXY]-1-HYDROXY-2-OXA-6,9-DIAZA-1-PHOSPHAUNDECAN-11-YLIC-ACID-.KAPPA.N6,.KAPPA.N9,.KAPPA.011]1-OXIDATO(6-)]-, HEXAHYDROGEN, ITS SALTS, PHARMACEUTICAL AGENTS THAT CONTAIN THESE COMPLEXES, THEIR USE IN TREATMENT AND AS ADDITIVES IN DIAGNOSIS, AS WELL AS PROCESSES FOR THE PRODUCTION OF THE COMPLEXES AND AGENTS |
| 9636427, | Feb 19 2008 | GUERBET | Process for preparing a pharmaceutical formulation of contrast agents |
| 9655983, | Feb 19 2008 | GUERBET | Process for preparing a pharmaceutical formulation of contrast agents |
| 9907866, | Feb 19 2008 | GUERBET | Process for preparing a pharmaceutical formulation of contrast agents |
| Patent | Priority | Assignee | Title |
| 4478816, | Jun 07 1982 | GEORGETOWN UNIVERSITY, | Rare earth/chelating agent complex for digital fluoroscopy |
| 4647447, | Jul 24 1981 | Schering Aktiengesellschaft | Diagnostic media |
| 4822594, | Jan 27 1987 | Contrast enhancing agents for magnetic resonance images | |
| GB736432, |
| Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
| Jun 22 1989 | Mallinckrodt Medical, Inc. | (assignment on the face of the patent) | / | |||
| Feb 27 1991 | MALLINCKRODT, INC , A CORP OF DE | MALLINCKRODT MEDICAL, INC , A DE CORP | ASSIGNMENT OF ASSIGNORS INTEREST | 005635 | /0379 |
| Date | Maintenance Fee Events |
| Jun 30 1995 | M183: Payment of Maintenance Fee, 4th Year, Large Entity. |
| Jul 26 1995 | ASPN: Payor Number Assigned. |
| Jul 20 1999 | M184: Payment of Maintenance Fee, 8th Year, Large Entity. |
| Jul 21 2003 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
| Date | Maintenance Schedule |
| Jan 21 1995 | 4 years fee payment window open |
| Jul 21 1995 | 6 months grace period start (w surcharge) |
| Jan 21 1996 | patent expiry (for year 4) |
| Jan 21 1998 | 2 years to revive unintentionally abandoned end. (for year 4) |
| Jan 21 1999 | 8 years fee payment window open |
| Jul 21 1999 | 6 months grace period start (w surcharge) |
| Jan 21 2000 | patent expiry (for year 8) |
| Jan 21 2002 | 2 years to revive unintentionally abandoned end. (for year 8) |
| Jan 21 2003 | 12 years fee payment window open |
| Jul 21 2003 | 6 months grace period start (w surcharge) |
| Jan 21 2004 | patent expiry (for year 12) |
| Jan 21 2006 | 2 years to revive unintentionally abandoned end. (for year 12) |